Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma

Hormone Research

Volumn 60, Issue 4, 2003, Pages 174-180

  Ranke, Michael B ^a   Maier, Klaus Peter ^b   Schweizer, Roland ^a   Stadler, Bernd ^b   Schleicher, Sabine ^a   Elmlinger, Martin W ^a   Flehmig, Bertram ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b KLINIKUM ESSLINGEN   (Germany)

Author keywords

Hepatocellular carcinoma; Insulin like growth factor binding protein 2; Insulin like growth factor I

Indexed keywords

ALPHA FETOPROTEIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; EVALUATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; SEROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS;

EID: 0141924092     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073229     Document Type: Article

References (48)

1. Jones JL, Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995;16:3-34.
2. LeRoith D, Clemmons D, Nissley P, Rechler MM: Insulin-like growth factors in health and disease. Ann Intern Med 1992;116:854-862.
3. Rosen CJ, Pollak M: Circulating IGF-I: New perspectives for a new century. Trends Endocrinol Metab 1999;10:136-141.
4. Collett-Solberg PF, Cohen P: Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine 2000;12:121-136.
5. Elmlinger MW, Deininger MH, Schuett BS, Meyermann R, Duffner F, Grote EF, Ranke MB: In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with tumor grade. Endocrinology 2001;142:1652-1658.
6. Müller H, Oh Y, Lernbecher T, Blum WF, Rosenfeld RG: Insulin-like growth factor binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab 1994;79:428-432.
7. Cohen P: Serum insulin-like growth factor-I levels and prostate cancer - Interpreting the evidence. J Natl Cancer Inst 1998;90:876-879.
8. Ho PJ, Baxter RC: Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 1997;46:333-342.
9. Donaghy A, Ross R, Gimson A, Hughes SC, Holly J, Williams R: Growth hormone, insulin-like growth factor I, insulin-like growth factor binding protein 1 and 3 in chronic liver disease. Hepatology 1995;21:680-688.
10. Holt RI, Baker AJ, Jones JS, Miell JP: The insulin-like growth factor and binding protein axis in children with end-stage liver disease, before and after orthoptic liver transplantation. Pediatr Transplant 1988;2:76-84.
11. Schimpf RM, Lebrec D, Donnadieu M: Somatomedin production in normal adults and cirrhotic patients. Acta Endocrinol (Copenh) 1977;86:355-362.
12. Buzelli G, Dattolo P, Pinzani M, Brocchi A, Romano S, Tentilini P: Circulating growth hormone and insulin-like growth factor-I in non-alcoholic liver cirrhosis with and without superimposed hepatocarcinoma: Evidence of an altered circadian rhythm. Am J Gastroenterol 1993;88:1744-1748.
13. Cariani E, Lasserre C, Kemeny F, Franco D, Brechot C: Expression of insulin-like growth factor II, alpha fetoprotein and hepatitis B virus transcripts in human primary liver cancer. Hepatology 1991;13:644-649.
14. Stuver SO, Kuper H: IGF-1 in hepatocellular carcinoma. Int J Cancer 2000;87:118-121.
15. Wu JC, Daughday WH: Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. J Lab Clin Med 1988;112:589-594.
16. Ranke MB, Schweizer R, Elmlinger MW, Weber K, Binder G, Schwarze CP, Wollmann HA: Significance of basal IGF-I, IGFBP-3 and IGFBP-2 measurements in the diagnostics of short stature in children. Horm Res 2000;54:60-68.
17. Blum WF: Insulin-like growth factors and their binding proteins; in Ranke MB (ed): Diagnostics of Endocrine Function in Children and Adolescents. Heidelberg, Barth, 1996, pp 190-218.
18. Blum WF, Horn N, Kratzsch J, Jorgensen JO, Juul A, Teale D, Mohnike K, Ranke MB: Clinical studies of IGFBP-2 by radioimmunoassay. Growth Regul 1993;3:100-104.
19. Clemmons DR, Snyder DK, Busby WHJ: Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 1991;73:727-733.
20. Rajaram S, Baylink DJ, Mohan S: Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions. Endocr Rev 1997;18:801-831.
21. Akmal SN, Yun K, MacLay J, Higami Y, Ikeda T: Insulin-like growth factor 2 and insulin-like growth factor binding protein 2 expression in hepatoblastoma. Hum Pathol 1995;26:846-851.
22. Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS: Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 1997;82:2308-2313.
23. Hofmann J, Wegmann B, Hackenberg R, Kunzmann R, Schulz KD, Havemann K: Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells. J Cancer Res Clin Oncol 1994;120:137-142.
24. Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J, Karasik A: Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer 1996;73:1069-1073.
25. Karasik A, Menczer J, Pariente C, Kanety H: Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluid of epithelial ovarian cancer. J Clin Endocrinol Metab 1994;78:271-276.
26. Vincent TS, Garvin AJ, Gramling TS, Hazen-Martin DJ, Re GG, Sens DA: Expression of insulin-like growth factor binding protein 2 (IGFBP-2) in Wilms' tumors. Pediatr Pathol 1994;14:723-730.
27. Zumkeller W, Schwander J, Mitchell CD, Morrell DJ, Schofield PN, Preece MA: Insulin-like growth factor (IGF)-I, -II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms' tumour. Eur J Cancer 1993;29:1973-1977.
28. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG: Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993;76:1031-1035.
29. Cohen P, Peehl DM, Rosenfeld RG: The IGF axis in the prostate. Horm Metab Res 1994;26:81-84.
30. Kratzsch J, Blum WF, Schenker E, Keller E: Regulation of growth hormone (GH), insulin-like growth factor (IGF)-I, IGF binding proteins-1, -2, -3 and GH binding protein during progression of liver cirrhosis. Exp Clin Endocrinol Diabetes 1995;10:285-291.
31. Tennant MK, Thrasher JBTPA, Birnbaum RS, Plymate SR: Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 1996;81:411-420.
32. Wex H, Vorwerk P, Mohnike K, Bretschneider D, Kluba U, Aumann V, Blum WF, Mittler U: Elevated serum levels of IGFBP-2 found in children suffering from acute leukemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone. Br J Cancer 1998;78:515-520.
33. Elmlinger MW, Wimmer K, Biemer F, Blum WF, Ranke MB, Dannecker GE: Insulin-like growth factor binding protein 2 is differentially expressed in leukaemic B- and T-cell lines. Growth Regul 1996;6:152-157.
34. Mohnike KL, Kluba U, Mittler U, Aumann V, Vorwerk P, Blum WF: Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins-2 and -3 in children with acute lymphoblastic leukaemia. Eur J Pediatr 1996;155:81-86.
35. Bachrach LK, Nänto-Salonen K, Tapanainen P, Rosenfeld RG, Gargosky SE: Insulin-like growth factor binding protein production in human follicular thyroid carcinoma cells. Growth Regul 1995;5:109-118.
36. Boulle N, Baudin E, Gicquel C, Logié A, Bertherat J, Penfornis A, Bertagna X, Luton J-P, Schlumberger M, Le Bouc Y: Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumours. Eur J Endocrinol 2001;144:29-36.
37. Chadelat K, Boule M, Corroyer S, Fauroux B, Delaisi B, Tournier G, Clement A: Expression of insulin-like growth factors and their binding proteins by bronchoalveolar cells from children with and without interstitial lung disease. Eur Respir J 1998;11:1329-1336.
38. Lee DY, Kim SJ, Lee YC: Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 1999;14:401-404.
39. Reeve JG, Kirby LB, Brinkman A, Hughes SA, Schwander J, Bleehen NM: Insulin-like growth-factor-binding protein gene expression and protein production by human tumour cell lines. Int J Cancer 1992;51:818-821.
40. El Atiq F, Garrouste F, Remacle-Bonnet M, Sastre BPG: Alterations in serum levels of insulin-like growth factors and insulin-like growth factor binding proteins in patients with colorectal cancer. Int J Cancer 1994;57:491-497.
41. Kutoh E, Margot JB, Schwander J: Identification and characterization of the putative retinoblastoma control element of the rat insulin-like growth factor binding protein-2 gene. Cancer Lett 1999;136:187-194.
42. Mottala C, MacDonald R, Brackett J, Mole J, Anderson J, Zcech M: Purification and amino-terminal sequence of an insulin-like growth factor binding protein by rat liver BRL-3A cells. J Biol Chem 1986;261:11180-11188.
43. Gray SG, Eriksson T, Ekström C, Holm S, von Schweinitz D, Kogner P, Sandstedt B, Pietsch T, Ekström TJ: Altered expression of members of the IGF-axis in hepatoblastomas. Br J Cancer 2000;82:1561-1567.
44. Looijenga LH, Verkerk AJ, De Groot N, Hochberg AA, Oosterhuis JW: H19 in normal development and neoplasia. Mol Reprod Dev 1997;46:419-439.
45. Li X, Nong Z, Ekstrom C, Larsson E, Nordlinder H, Hofmann WJ, Trautwein C, Odenthal M, Dienes P, Ekstrom TJ, Schirmacher P: Disrupted IGF-2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 1997;57:2048-2054.
46. Takeda S, Kondo M, Kumada T: Allelic expression of the insulin-like growth factor 2 gene in hepatocellular carcinoma and underlying disease. Oncogene 1996;12:1589-1592.
47. Yamada T, DeSouza AT, Finkelstein S, Jirtle RL: Loss of gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 1997;94:10351-10355.
48. Kuper H, Tzonou A, Kaklamani E, Hadziyannis S, Tasopoulous N, Lagiou P, Trichopoulous D, Stuver S: Hepatitis B and C viruses in the etiology of hepatocellular carcinoma: A study in Greece using third generation assays. Cancer Causes Control 2000;11:171-175.